Affymetrix, Millennium Partner in R&D and Supply Deal | GenomeWeb

SAN FRANCISCO, Oct. 24 – Millennium Pharmaceuticals entered a four-year R&D and volume discount supply agreement with Affymetrix, the companies announced Wednesday.

The deal includes co-development of gene expression array processes and applications for drug discovery and development, including next generation GeneChip technology applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.